<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00668967</url>
  </required_header>
  <id_info>
    <org_study_id>A6661003</org_study_id>
    <nct_id>NCT00668967</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study Of Verapamil</brief_title>
  <official_title>Bioequivalence Study Of Verapamil (Covera HS) 240 Mg Extended Release Tablets Produced By Alza Corporation, Vacaville And Pfizer Inc, Puerto Rico: A Two Sequence, Four-Way Crossover Design, Single Dose, Open-Label, Randomized Study In Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate bioequivalence of single doses of two verapamil
      formulations
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary study endpoints will be AUClast, AUCinf and Cmax of R- and S-verapamil.</measure>
    <time_frame>5 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary endpoints will include Tmax and t1/2 of R- and S-verapamil and S- and R- norverapamil, as data permit. AUClast, AUCinf and Cmax of R- and S-norverapamil as data permit.</measure>
    <time_frame>5 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability as assessed by reported adverse events, safety lab test and vital signs</measure>
    <time_frame>5 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">79</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Reference</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>marketed extended release verapamil tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Test</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>reformulated extended release verapamil tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>verapamil</intervention_name>
    <description>240 mg extended release tablets once daily at bedtime for 28 days</description>
    <arm_group_label>Reference</arm_group_label>
    <other_name>Covera HS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>verapamil</intervention_name>
    <description>240 mg extended release tablets once daily at bedtime for 28 days</description>
    <arm_group_label>Test</arm_group_label>
    <other_name>Covera HS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and/or female subjects

          -  Mass Index (BMI) of approximately 18 to 30 kg/m2

        Exclusion Criteria:

          -  Any condition possibly affecting drug absorption

          -  A positive urine drug screen
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A6661003&amp;StudyName=Bioequivalence%20Study%20Of%20Verapamil</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>July 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 25, 2008</study_first_submitted>
  <study_first_submitted_qc>April 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2008</study_first_posted>
  <last_update_submitted>July 7, 2009</last_update_submitted>
  <last_update_submitted_qc>July 7, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 8, 2009</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <keyword>Cardiovascular Diseases</keyword>
  <keyword>Hypertension</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Verapamil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

